US4615885A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical composition containing urokinase
Assignee: Terumo Corp
•
Filing: 1984-10-09
•
Granted: 1986-10-07
•
Expires: 2004-10-09
Abstract
Abstract A pharmaceutical composition containing urokinase and a physiological absorption enhancer comprising higher fatty acids, a polyalkylene glycol and calcium is disclosed. Whereas urokinase which is decomposed and inactivated in the stomach and is poorly absorbed from the intestinal tract cannot be orally administered, it can be orally administered in the form of the present composition by applying an enteric coating, because urokinase in the composition is highly absorbable from the intestinal tract. It is desirable in the present composition in view of the stability and sustained absorbability that urokinase is contained in said composition in the form of a liposome preparation in which the urokinase is incorporated in voids of the liposome. The components are incorporated in the present composition at a ratio of 0.01-2 mg. of the higher fatty acid, 0.01-5 mg. of the polyalkylene glycol and 0.0001-0.1 mg. of the calcium per 100 units of urokinase. The present composition is satisfactory for use as a thrombolytic agent.
Inventors
- 👤 Fujio Nakagame
- 👤 Haruo Honda
- 👤 Teppei Maruyama
- 👤 Noriko Saito
- 👤 Tomoaki Kimoto
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 20:49
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; A61K9/1277; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/49; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K9/20; A61K9/2004; A61K9/2013; A61K9/2022; A61K9/2031; A61K9/48; A61K9/4841; A61K9/4858; A61K9/4866; A61K9/4891
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
37 words
A pharmaceutical composition containing urokinase comprising a therapeutically effective amount of urokinase and an effective amount of physiological absorption enhancer, said enhancer comprising one or more higher fatty acids, a polyalkylene glycol and a pharmaceutically acceptable calcium.
Claim 2
Dependent Claim
37 words
A pharmaceutical composition containing urokinase comprising a therapeutically effective amount of urokinase and an effective amount of physiological absorption enhancer, said enhancer comprising one or more higher fatty acids, a polyalkylene glycol and a pharmaceutically acceptable calcium.
Claim 3
Dependent Claim
18 words
The pharmaceutical composition containing urokinase according to claim 1 wherein the higher fatty acid contains 10-20 carbon atoms.
Claim 4
Dependent Claim
23 words
The pharmaceutical composition containing urokinase according to claim 2 wherein the higher fatty acid contains 1-4 double bonds and 18-14 20 carbon atoms.
Claim 5
Dependent Claim
17 words
The pharmaceutical composition containing urokinase according to claim 3 wherein the higher fatty acid is oleic acid.
Claim 6
Dependent Claim
17 words
The pharmaceutical composition containing urokinase according to claim 3 wherein the polyalkylene glycol is a polyethylene glycol.
Claim 7
Dependent Claim
20 words
The pharmaceutical composition containing urokinase as in any one of claims 1-5 wherein the urokinase is an urokinase-carrying liposome preparation.
Claim 8
Dependent Claim
31 words
The pharmaceutical composition containing urokinase according to claim 6 wherein the urokinase-carrying liposome preparation is a liposome preparation the membrane material of which contains a lipid and a higher fatty acid.
Claim 9
Dependent Claim
16 words
The pharmaceutical composition containing urokinase according to claim 6 wherein the lipid is a hydrogenated lecithin.
Claim 10
Dependent Claim
36 words
The pharmaceutical composition containing urokinase according to claim 1 which contains 0.01-2 mg. of the higher fatty acid, 0.01-5 mg. of the polvalkylene glycol and 0.0001-0.1 mg. of the calcium per 100 units of the urokinase.
Claim 11
Dependent Claim
16 words
The pharmaceutical composition containing urokinase according to claim 7 wherein the lipid is a hydrogenated lecithin.
Claim 12
Dependent Claim
23 words
The pharmaceutical composition containing urokinase according to claim 1 wherein said calcium compound is calcium chloride, calcium lactate, calcium phosphate or calcium gluconate.
Claim 13
Dependent Claim
35 words
The pharmaceutical composition containing urokinase according to claim 9 wherein the higher fatty acid contains 1-4 double bonds and 18-20 carbon atoms, the polyalkyleneglycol is a polyetheleneglycol and the urokinase is an urokinase-carrying liposome preparation.
Claim 14
Dependent Claim
52 words
The pharmaceutical composition containing urokinase according to claim 12 wherein said higher fatty acid is in an amount of from 0.05 to 0.5 mg, said polyalkyleneglycol is in an amount from 0.1 to 1 mg and said calcium is in an amount from 0.0005 to 0.005 mg per 100 units of urokinase.
Claim 15
Dependent Claim
46 words
The pharmaceutical composition containing urokinase according to claim 13 wherein said polyethylene glycol has a degree of polymerization of from 160 to 200 and wherein the urokinase-carrying liposome preparation is a liposome preparation the membrane material of which contains a lipid and a higher fatty acid.
Claim 16
Dependent Claim
39 words
The pharmaceutical composition containing urokinase according to claim 14 wherein the higher fatty acid is oleic acid, wherein the lipid is a hydrogenated lecithin and wherein said calcium compound is calcium chloride, calcium lactate, calcium phosphate or calcium gluconate.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-10-06 | 1990-04-07 | 1990-10-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-10-06 | 1994-04-07 | 1994-10-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-10-06 | 1998-04-07 | 1998-10-07 | $7700.00 | Window Closed / Lapsed |